Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Elevance Health (ELV)

Elevance Health Q4 2023 revenue rises 7% to $42.5 billion; 2024 EPS outlook above $34.29

Positive Impact 4 of 5 earnings Written later

Elevance Health reported fourth-quarter and full-year 2023 results in a press release furnished under Item 2.02 of this 8-K. Quarterly operating revenue rose 7.0% to $42.5 billion and GAAP diluted EPS rose 1.1% to $3.63, while the company set a full-year 2024 GAAP diluted EPS outlook of greater than $34.29, compared with $25.22 for 2023, and raised its quarterly dividend 10.1% to $1.63 per share.

Key points

  • 4Q 2023 operating revenue $42.5 billion, up 7.0%; GAAP diluted EPS $3.63, up 1.1%; adjusted diluted EPS $5.62, up 15.2%
  • FY 2024 GAAP diluted EPS outlook greater than $34.29; adjusted diluted EPS outlook greater than $37.10, versus FY 2023 GAAP diluted EPS of $25.22
  • Quarterly dividend increased 10.1% to $1.63 per share
  • 4Q 2023 operating margin was 3.0%, down from 3.2% in 4Q 2022

The filing

CompanyElevance Health (ELV)
Form8-K, current report
Filed with the SECJan 24, 2024, 6:04 AM ET
Accession number0001193125-24-013498

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 24, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.